Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00435
|
|||||
Drug Name |
Simvastatin
|
|||||
Synonyms |
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; Cholestat; Coledis; Colemin; Corolin; DRG-0320; Denan; KS-1113; L 644128-000U; Labistatin; Lipex; Lipovas; Lodales; MK 0733; MK 733; MK-0733; MK-733; MK733; Medipo; Nivelipol; Pantok; Rendapid; Simcard (TN); Simlup (TN); Simovil; Simvacor (TN); Simvast CR; Simvastatin & Primycin; Simvastatin (JAN/USP/INN); Simvastatin [USAN:INN:BAN]; Simvastatin, Compactin; Simvastatina; Simvastatina [Spanish]; Simvastatine; Simvastatine [French]; Simvastatinum; Simvastatinum [Latin]; Sinvacor; Sivastin; Synvinolin; TNP00259; Vasotenal; Zocor; Zocor (TN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; Zocord; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Hypercholesterolemia [ICD11: 5C80.0] | Approved | [1] | |||
Therapeutic Class |
Anticholesteremic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C25H38O5
|
|||||
Canonical SMILES |
CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
|
|||||
InChI |
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
|
|||||
InChIKey |
RYMZZMVNJRMUDD-HGQWONQESA-N
|
|||||
CAS Number |
CAS 79902-63-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 418.6 | Topological Polar Surface Area | 72.8 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
4.7
|
|||||
PubChem CID | ||||||
PubChem SID |
10321271
, 10852028
, 11113242
, 11342166
, 11362349
, 11364611
, 11367173
, 11369735
, 11371657
, 11374383
, 11377897
, 11466893
, 11468013
, 11485617
, 11486566
, 11487751
, 11489487
, 11490485
, 11492447
, 11495531
, 11528633
, 11533326
, 12013879
, 12146013
, 14831549
, 14929313
, 24724617
, 25819951
, 26612685
, 26680673
, 26759532
, 34718442
, 46508654
, 47365442
, 47440515
, 47736737
, 47885633
, 47885634
, 48110715
, 48334759
, 48416540
, 496592
, 49698671
, 50086525
, 50100555
, 50100556
, 648581
, 7847500
, 7980599
, 8183649
|
|||||
ChEBI ID |
ChEBI:9150
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
References | ||||||
1 | Simvastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
3 | Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. | |||||
4 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.